CXCR4 and gastric cancer: We revealed the potential anti-tumor effects and underlying mechanisms of regorafenib in gastric cancer cells, and CXCR4 might mediated the anti-tumor effect of gastric cancer cell to regorafenib, and might be a novel biomarker for patients selecting of regorafenib.